NFE2L2 and neoplasm: On the other hand, MIR4435-2HG can lead to tumor progression by affecting Wnt, TGF-β/SMAD, Nrf2/HO-1, PI3K/AKT, MAPK/ERK, and FAK/AKT/β‐catenin signaling pathways.